Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system

Drug Saf. 2013 Oct;36 Suppl 1:S59-72. doi: 10.1007/s40264-013-0099-6.


Background: Observational healthcare data offer the potential to enable identification of risks of medical products, but appropriate methodology has not yet been defined. The new user cohort method, which compares the post-exposure rate among the target drug to a referent comparator group, is the prevailing approach for many pharmacoepidemiology evaluations and has been proposed as a promising approach for risk identification but its performance in this context has not been fully assessed.

Objectives: To evaluate the performance of the new user cohort method as a tool for risk identification in observational healthcare data.

Research design: The method was applied to 399 drug-outcome scenarios (165 positive controls and 234 negative controls across 4 health outcomes of interest) in 5 real observational databases (4 administrative claims and 1 electronic health record) and in 6 simulated datasets with no effect and injected relative risks of 1.25, 1.5, 2, 4, and 10, respectively.

Measures: Method performance was evaluated through Area Under ROC Curve (AUC), bias, and coverage probability.

Results: The new user cohort method achieved modest predictive accuracy across the outcomes and databases under study, with the top-performing analysis near AUC >0.70 in most scenarios. The performance of the method was particularly sensitive to the choice of comparator population. For almost all drug-outcome pairs there was a large difference, either positive or negative, between the true effect size and the estimate produced by the method, although this error was near zero on average. Simulation studies showed that in the majority of cases, the true effect estimate was not within the 95 % confidence interval produced by the method.

Conclusion: The new user cohort method can contribute useful information toward a risk identification system, but should not be considered definitive evidence given the degree of error observed within the effect estimates. Careful consideration of the comparator selection and appropriate calibration of the effect estimates is required in order to properly interpret study findings.

MeSH terms

  • Area Under Curve
  • Cohort Studies*
  • Drug-Related Side Effects and Adverse Reactions / diagnosis*
  • Humans
  • Research Design*
  • Risk Assessment / methods*